Suven Life Sciences announces Phase 3 clinical trial of Masupirdine
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
Serum buys 50 per cent stake in Indian joint venture of SCHOTT Kaisha
Investment of Rs 235 crores to add 411 beds in the next 18 months
National Accreditation Board for Hospitals & Healthcare Providers (NABH) is a constituent board of the Quality Council of India, set up to establish and operate accreditation programmes for healthcare organisations
The MoU was signed on World Organ Donation Day which falls on August 13
This is the first of its kind vaccine for Covid 19 to get the go-ahead
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose
Subscribe To Our Newsletter & Stay Updated